UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 13 26, 2026

LB Pharmaceuticals Inc

(Exact name of registrant as specified in its charter)

Delaware	001-42831	81-1854347
(State of incorporation)	(Commission File No.)	(IRS Employer Identification No.)
(state or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

One Pennsylvania Plaza, Suite 1025

New York, NY

10119

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (212) 605-0300

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ~~(see General Instruction A.2. below)~~:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	~~TradingSymbol(s)~~Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	LBRX	The Nasdaq Stock Market LLC
Common Stock, $0.0001 par value per share	LBRX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.02 ~~Departure~~Results of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Condition.

~~Departure~~On March 26, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2025. A copy of ~~Director~~the press release is furnished hereto as Exhibit 99.1.

OnThe ~~March 13~~information in this Item 2.02, ~~2026~~including Exhibit 99.1 attached hereto, ~~Zachary~~is ~~Prensky~~being ~~notified~~furnished ~~the~~and ~~Board~~shall ofnot ~~Directors~~be ~~(the~~deemed “~~Board~~filed”) for purposes of LBSection 18 ~~Pharmaceuticals~~of ~~Inc~~the Securities Exchange Act of 1934, as amended (the “~~Company~~Exchange Act”) ofor ~~his~~otherwise ~~intent~~subject to ~~retire~~the asliabilities aof ~~member~~that ofsection. ~~the~~The ~~Board~~information ~~and~~contained ~~therefore~~in ~~not~~this ~~stand~~Item ~~for~~2.02 ~~reelection~~and atin the ~~Company’s~~accompanying ~~2026~~exhibit ~~annual~~is ~~meeting~~not ofincorporated ~~stockholders~~by ~~(the~~reference ~~“2026~~in ~~Annual~~any ~~Meeting”).~~filing ~~Accordingly,~~of ~~Mr. Prensky’s~~the ~~term~~Company asunder athe ~~director~~Securities ~~will~~Act ~~end~~of ~~when~~1933, ~~his~~as ~~current~~amended ~~term expires at~~ (the ~~2026~~“Securities ~~Annual~~Act”), ~~Meeting.~~or ~~Mr. Prensky~~the ~~will~~Exchange ~~remain~~Act, aswhether amade ~~member~~before ofor after the ~~Board~~date ~~and~~hereof, asregardless aof ~~member~~any ofgeneral ~~the~~incorporation ~~Nominating~~language ~~and~~in ~~Corporate~~such ~~Governance~~filing, ~~Committee~~except ofas ~~the~~shall ~~Board~~be ~~until~~expressly ~~the~~set ~~conclusion~~forth ofby ~~the~~specific ~~2026~~reference ~~Annual~~in ~~Meeting~~such filing.

~~Mr. Prensky’s~~Item ~~decision to resign was not a result of any disagreement with the Company on any matter related to the Company’s operations, policies or practices~~9.01 ~~Following~~Financial ~~his~~Statements ~~resignation date, Mr. Prensky is expected to provide consulting services to the Company. The Board thanks Mr. Prensky for his years of service~~ and ~~valuable contributions to the Company~~Exhibits.

~~In connection with Mr. Prensky’s separation from the Company, the Company and Mr. Prensky entered into an Amendment No. 1 to Transition, Separation, and Consulting Agreement~~ (~~the “Transition Agreement Amendment”~~d)~~, effective June~~ 3,Exhibits 2026, which amended that certain Transition, Separation, and Consulting Agreement, dated November 26, 2024 (the “Transition Agreement”). Pursuant to the Transition Agreement Amendment, Mr. Prensky will continue to provide consulting services as may be reasonably requested by the Company and receive the benefits described in the Transition Agreement. In addition, Mr. Prensky’s outstanding and unvested stock options are eligible to continue to vest for the duration of the term of the Transition Agreement Amendment.

The foregoing description is a summary of the Transition Agreement Amendment and is qualified in its entirety by reference to the full text of the Transition Agreement Amendment, a copy of which will be filed as exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.


Exhibit No.		Description

99.1		Press Release dated March 26, 2026.

104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


LB PHARMACEUTICALS INC

By:		/s/ Heather Turner
		Heather Turner Chief Executive Officer

Dated: March 26, 2026

LB Pharmaceuticals Inc

Date: March 16, 2026

/s/ Heather Turner

Heather Turner

Chief Executive Officer

Filing Compare · LB PHARMACEUTICALS INC